論文

査読有り
2014年3月

Factors influencing survival outcome for radiotherapy for biliary tract cancer: A multicenter retrospective study

Radiotherapy and Oncology
  • Yasuo Yoshioka
  • Kazuhiko Ogawa
  • Hirobumi Oikawa
  • Hiroshi Onishi
  • Nobue Uchida
  • Toshiya Maebayashi
  • Naoto Kanesaka
  • Tetsuro Tamamoto
  • Hirofumi Asakura
  • Takashi Kosugi
  • Kazuo Hatano
  • Michio Yoshimura
  • Kazunari Yamada
  • Sunao Tokumaru
  • Kenji Sekiguchi
  • Masao Kobayashi
  • Toshinori Soejima
  • Fumiaki Isohashi
  • Kenji Nemoto
  • Yasumasa Nishimura
  • 全て表示

110
3
開始ページ
546
終了ページ
552
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.radonc.2014.01.003
出版者・発行元
ELSEVIER IRELAND LTD

Purpose To seek for the possible factors influencing overall survival (OS) with radiotherapy (RT) for biliary tract cancer. Materials and methods Data were collected retrospectively from RT database of 31 institutions in Japan. All patients underwent at least external beam RT. The factors influencing OS were investigated. Results Data of 498 patients were analyzed. Median OS of the 212 patients who underwent surgery was significantly better than that of the 286 patients without surgery (31 vs. 15 months, p < 0.001). The OS for the R0 or R1 resection group was significantly longer than that for the R2 or non-surgery group, as well as for n0 compared to n1 (all p < 0.001). Chemoradiotherapy (CRT), both sequential and concurrent, resulted in a better OS than RT alone for the n1 group (31 vs. 13 months, p < 0.001), and marginally better for the R0/R1 group (p = 0.065; p = 0.054 for concurrent CRT). However, no such benefit was observed for the R2/non-surgical patients. Multivariate analysis identified performance status, clinical stage, and surgery as significant factors. Conclusion Surgery, especially R0/R1 resection, seemed as the gold standard for treatment of biliary tract cancer including RT, even in the highly heterogeneous population obtained from the multicenter retrospective study. The possibility was shown that CRT yielded better survival benefit especially for n1 patients. We recommend that future prospective trials include an arm of adjuvant CRT at least for n1 and possibly R0/R1 patients. © 2013 Elsevier Ireland Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.radonc.2014.01.003
J-GLOBAL
https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702212411250948
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/24560766
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000336110200028&DestApp=WOS_CPL
Scopus
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84899536636&origin=inward
Scopus Citedby
https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84899536636&origin=inward
ID情報
  • DOI : 10.1016/j.radonc.2014.01.003
  • ISSN : 0167-8140
  • eISSN : 1879-0887
  • J-Global ID : 201702212411250948
  • PubMed ID : 24560766
  • SCOPUS ID : 84899536636
  • Web of Science ID : WOS:000336110200028

エクスポート
BibTeX RIS